NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Recruitment Status: Enrolling by invitation

NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Sponsor

Poseida Therapeutics, Inc.

Collaborator

California Institute for Regenerative Medicine (CIRM)

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT03741127

Official Title: Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

First Posted: November 14, 2018

Click here for details on Clinicaltrials.gov

---

CART - BCMA : National Cancer Institute

Biological: P-BCMA-101 CAR-T cells

Drug: Rimiducid

---